%0 Journal Article
%T A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
%A Parrondo RD
%A Dutta N
%A LaPlant BR
%A Elliott J
%A Fernandez A
%A Zimmerman A
%A Cicco G
%A Han B
%A Heslop K
%A Chapin D
%A Sher T
%A Roy V
%A Rasheed A
%A Das S
%A Chanan-Khan AA
%A Paulus A
%A Ailawadhi S
%J Br J Haematol
%V 204
%N 5
%D 2024 May 29
%M 38286472
%F 8.615
%R 10.1111/bjh.19320
%X This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow-up time of 25.7 months, the median progression-free survival (PFS) was 22.9 months. While the primary end-point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.